Comprehensive narrative review focusing on retatrutide, a novel triple agonist medication designed to treat obesity and type 2 diabetes mellitus. It outlines the increasing global prevalence of these conditions and the need for innovative therapeutic approaches. The article details retatrutide’s mechanism of action, highlighting its synergistic effects on glucagon, gastric inhibitory polypeptide, and glucagon-like peptide-1 receptors. Furthermore, it summarizes preclinical and clinical trial outcomes, demonstrating the drug’s significant efficacy in weight reduction, glycemic control, and improvement of related metabolic factors. The review also compares retatrutide’s effectiveness and side effects to existing single and dual-receptor agonists and DPP-4 inhibitors, concluding with a discussion of its future therapeutic potential and remaining research needs.
Audio Overview (Google NotebookLM)
(27 minutes 12 seconds)
